Start Up Funds

Source: University of Pittsburgh Cancer Institute   
Duration: 07/01/2008 − 06/31/2011

Hillman Fellow for Innovative Cancer Research Award

Source: Hillman Foundation
Duration: 01/01/2011 − 12/31/2011

NIH/NIAID U24 Cooperative Agreement

Source: National Institute of Allergy and Infectious Diseases (NIAID)
Duration: 03/15/2009 − 02/28/2014
Title: Novel Modifiers of Toll-like and RIG-like Receptor Signaling.
Major Goal: High throughput screening to identify chemical and small interfering RNA modifiers, which will specifically modulate Toll-like Receptor 3, Retinoic acid Inducible gene I and Toll-like receptor 7 signaling pathways. Summary on NIH NLM

Completed Funding

Scientist Development Grant

Source: American Heart Association   
Duration: 01/01/2007 − 12/31/2010                   
Title: Novel Small-Molecule inhibitors of TLR3 – IRF-3 signaling pathway
Major Goal: Develop specific TLR3 antagonists to use for the treatment of virus infection mediated inflammatory diseases using a cell-based high-throughput screening of small-molecule chemical library.